Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classement en actions #4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prix de l'action
$27.18
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$3.38B
Changement (1 jour)
-1.41%
Changement (1 an)
202.34%
Pays
US
Échange Tango Therapeutics, Inc. (TNGX)

Catégorie

Healthcare
Historique du rendement du dividende pour Tango Therapeutics, Inc. (TNGX)
Le rendement du dividende (TTM) de Tango Therapeutics, Inc. (symbole boursier : TNGX) au 2023-12-31 est : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Tango Therapeutics, Inc. (TNGX) de 2019 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL